Jefferies Financial Group Inc. Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Jefferies Financial Group Inc. grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 141.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 96,849 shares of the medical equipment provider’s stock after acquiring an additional 56,742 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Hologic were worth $6,982,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in HOLX. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co grew its holdings in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new position in Hologic during the 4th quarter valued at about $60,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company’s stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. Stephens reiterated an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Evercore ISI cut their price target on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Friday, May 2nd. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.58.

Hologic Price Performance

Shares of HOLX stock opened at $56.74 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $12.73 billion, a P/E ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54. The company’s 50-day simple moving average is $59.43 and its two-hundred day simple moving average is $68.17. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $1.03 EPS. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.